SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?


To: WTDEC who wrote (264)1/27/1999 10:05:00 PM
From: Steve  Respond to of 496
 
Thanks for the link. I enjoyed listening to Dr. Smith. However, I still believe he needs to sell the company. My broker believes the company will be sold and thinks that the buyout range is $17 to $20 at the most since the company has unproven technology and is a long ways from ever being profitable. I have to believe people have lost a ton of money from holding this stock. I still hope to break-even. Boy, this has been one bad investment.

I just hope Dr. Smith cares about doing what is best for the shareholders and not just want to be an independent commercial research house. The biotechs have come back strong and GLFD is bouncing down along the bottom. I think he could make more money for himself by getting options in some pharma. The options in GLFD are worthless; I hope he doesn't rewrite them for all of those employees who are underwater with their options. This would just be one more indication that we shareholders (I have been in this stock for over 2 years) got into a terrible investment.

I think exchanging our stock for stock in a large pharma that grows overtime would be best for all shareholders (like AGPH into WLA). GLFD just pops up and goes back down, pops up and goes back down. This isn't an investment. It seems to be a trading vehicle for those who do that type of thing. I would really like to know what some of the shareholders who are holding over 100,000 shares are thinking.

Regards,

Steve